Human tissue studies show higher levels of cross-linking AGEs (e.g., pentosidine) in diabetics with AAA and link these to slower growth, while interventional work indicates that disrupting or preventing AGE cross-linking accelerates elastin degradation and smooth-muscle injury—evidence that the cross-links themselves are protective in the aneurysm setting. Here, ELN is linked to triple-A syndrome.